FOXO4-DRI // Senolytic Peptide
A D-retro-inverso peptide that selectively kills senescent cells — the damaged 'zombie cells' that accumulate with age and drive chronic inflammation, tissue dysfunction, and accelerated aging. FOXO4-DRI disrupts the FOXO4-p53 interaction that keeps these cells alive, triggering targeted apoptosis while leaving healthy cells untouched.
Selective assassination of zombie cells.
Senescent cells are damaged cells that refuse to die. They secrete inflammatory molecules (SASP) that damage surrounding tissue and accelerate aging. FOXO4-DRI forces these specific cells into programmed death while healthy cells remain unaffected.
Quarterly burst — 3 to 5 days.
FOXO4-DRI uses the shortest burst protocol of any longevity peptide. 3–5 days of daily injections, repeated quarterly. The DRI modification provides extended stability, and senescent cell clearance is a periodic maintenance task, not a continuous process.
The landmark Baar et al. study.
The foundational research was published in Cell (2017) by Peter de Keizer's group at Erasmus University Medical Center. The study demonstrated that FOXO4-DRI selectively induced apoptosis in senescent cells in vivo, restoring fitness, fur density, and renal function in aged mice.
The selectivity mechanism is elegant: only senescent cells have the FOXO4-p53 nuclear interaction that FOXO4-DRI disrupts. Healthy cells with normal p53 distribution are unaffected. This avoids the collateral damage problem of non-selective senolytics like dasatinib + quercetin.
Human data remains extremely limited. The compound is expensive to synthesize due to D-amino acid requirements, and no formal clinical trials have been initiated. Community use is growing but relies entirely on preclinical data extrapolation.
Senolytic compound comparison.
| Compound | Type | Selectivity | Protocol | Data |
|---|---|---|---|---|
| FOXO4-DRI | Peptide | Highly selective (p53) | 3–5 day burst | Preclinical + community |
| Dasatinib + Quercetin | Drug + Flavonoid | Moderate | 3 days on/month | Phase 2 trials |
| Fisetin | Flavonoid | Low selectivity | 2-day burst/month | Phase 2 trials |
| Navitoclax | BCL-2 inhibitor | Moderate (platelet risk) | Continuous | Oncology trials |
What to watch for.
FOXO4-DRI's side effect profile is manageable with proper protocol adherence. Baseline blood work before starting and periodic monitoring during use is essential.
- Fatigue and malaise during burst (senescent cell die-off)
- Flu-like symptoms (immune clearance of dead cells)
- Injection site reactions
- Theoretical wound healing delay (senescent cells play roles in repair)
- Extremely limited human safety data
- Expensive — D-amino acid synthesis cost
- p16INK4a expression (senescent cell marker, if available)
- hsCRP / inflammatory markers (should decrease post-cycle)
- Complete blood count with differential
- Comprehensive metabolic panel
- Kidney function (BUN, creatinine, eGFR)
- Liver enzymes (ALT, AST)
- SA-β-galactosidase (senescence marker, if available)
- Epithalon for telomere + senolytic combined longevity protocol
- GHK-Cu for tissue repair after senescent cell clearance
- Do NOT combine with other senolytics (dasatinib/quercetin) simultaneously
- Space FOXO4-DRI bursts away from surgical recovery or wound healing
- BPC-157 for tissue support post-clearance
- Run quarterly — senescent cells accumulate continuously
- Lyophilized: store at -20°C (freezer) for long-term
- Short-term: refrigerate at 2–8°C
- Reconstituted: refrigerate, use within 7–10 days
- Protect from light — D-amino acids are stable but protect anyway
- Expensive compound — store carefully to avoid waste
Compounds that complement FOXO4-DRI.
The most selective senolytic ever designed — but proceed with caution.
FOXO4-DRI is mechanistically brilliant — the p53-targeting selectivity means it kills zombie cells while leaving healthy cells untouched. The Baar et al. data in aged mice is compelling. But the human data is virtually nonexistent, the compound is expensive, and the long-term effects of periodic senescent cell clearance in humans are unknown. If you proceed: quarterly 3–5 day bursts, comprehensive blood work before and after, pair with GHK-Cu for tissue repair in cleared niches, and work with a physician who understands the compound. This is cutting-edge longevity science — not a casual supplement.
Our free Protocol Guide includes the Senolytic Protocol — FOXO4-DRI burst timing, recovery support, biomarker tracking, and the complete Anti-Aging Stack.